JP2025121986A5 - - Google Patents
Info
- Publication number
- JP2025121986A5 JP2025121986A5 JP2025077691A JP2025077691A JP2025121986A5 JP 2025121986 A5 JP2025121986 A5 JP 2025121986A5 JP 2025077691 A JP2025077691 A JP 2025077691A JP 2025077691 A JP2025077691 A JP 2025077691A JP 2025121986 A5 JP2025121986 A5 JP 2025121986A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- polypeptide
- collagen
- linker
- binding domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856468P | 2019-06-03 | 2019-06-03 | |
| US62/856,468 | 2019-06-03 | ||
| JP2021571671A JP7680375B2 (ja) | 2019-06-03 | 2020-06-03 | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 |
| PCT/US2020/070113 WO2020247974A1 (en) | 2019-06-03 | 2020-06-03 | Methods and compositions for treating cancer with collagen binding drug carriers |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571671A Division JP7680375B2 (ja) | 2019-06-03 | 2020-06-03 | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025121986A JP2025121986A (ja) | 2025-08-20 |
| JP2025121986A5 true JP2025121986A5 (enExample) | 2025-12-17 |
Family
ID=73652058
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571671A Active JP7680375B2 (ja) | 2019-06-03 | 2020-06-03 | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 |
| JP2025077691A Pending JP2025121986A (ja) | 2019-06-03 | 2025-05-08 | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571671A Active JP7680375B2 (ja) | 2019-06-03 | 2020-06-03 | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220298225A1 (enExample) |
| EP (1) | EP3976111A4 (enExample) |
| JP (2) | JP7680375B2 (enExample) |
| CN (1) | CN114173822B (enExample) |
| AU (1) | AU2020289485A1 (enExample) |
| BR (1) | BR112021024438A2 (enExample) |
| CA (1) | CA3144535A1 (enExample) |
| MX (1) | MX2021014932A (enExample) |
| WO (1) | WO2020247974A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4671361A1 (en) * | 2023-02-20 | 2025-12-31 | The University of Osaka | CELL DESIGN MOLECULE THAT GIVES CELLS PROTEIN ADHESION PROPERTIES |
| US12605394B2 (en) | 2024-07-25 | 2026-04-21 | Visionary Assets, Llc | Compositions containing cannabinoid nanoparticles |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4879236A (en) | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5871986A (en) | 1994-09-23 | 1999-02-16 | The General Hospital Corporation | Use of a baculovirus to express and exogenous gene in a mammalian cell |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| CZ302706B6 (cs) | 1998-12-23 | 2011-09-14 | Pfizer Inc. | Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| WO2011060242A2 (en) * | 2009-11-13 | 2011-05-19 | Talecris Biotherapeutics, Inc. | Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2012112690A2 (en) * | 2011-02-16 | 2012-08-23 | Fabius Biotechnology | Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains |
| JP2014022858A (ja) | 2012-07-17 | 2014-02-03 | Murata Mfg Co Ltd | 電力増幅器 |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| EA201690746A1 (ru) | 2013-10-25 | 2016-12-30 | Фармасайкликс Элэлси | Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии |
| AU2015205530B8 (en) * | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| DK4074735T3 (da) * | 2014-08-28 | 2025-07-14 | Bioatla Inc | Betinget aktive kimæriske antigenreceptorer til modificerede t-celler |
| WO2016054107A1 (en) * | 2014-09-29 | 2016-04-07 | Counterpoint Biomedica Llc | Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polymers |
| ES2986067T3 (es) | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| SG11202104136YA (en) * | 2018-10-23 | 2021-05-28 | Dragonfly Therapeutics Inc | Heterodimeric fc-fused proteins |
-
2020
- 2020-06-03 JP JP2021571671A patent/JP7680375B2/ja active Active
- 2020-06-03 CA CA3144535A patent/CA3144535A1/en active Pending
- 2020-06-03 WO PCT/US2020/070113 patent/WO2020247974A1/en not_active Ceased
- 2020-06-03 US US17/596,118 patent/US20220298225A1/en active Pending
- 2020-06-03 BR BR112021024438A patent/BR112021024438A2/pt unknown
- 2020-06-03 AU AU2020289485A patent/AU2020289485A1/en active Pending
- 2020-06-03 MX MX2021014932A patent/MX2021014932A/es unknown
- 2020-06-03 CN CN202080055104.6A patent/CN114173822B/zh active Active
- 2020-06-03 EP EP20818032.3A patent/EP3976111A4/en active Pending
-
2025
- 2025-05-08 JP JP2025077691A patent/JP2025121986A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025121986A5 (enExample) | ||
| Li et al. | Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL | |
| US6399068B1 (en) | Method of treatment with a non-antigenic toxin-conjugate and fusion protein of internalizing receptor system | |
| US8920777B2 (en) | Toxins and radionuclides coupled to IGF-1 receptor ligands for treatment of cancer | |
| Curnis et al. | NGR-tagged nano-gold: A new CD13-selective carrier for cytokine delivery to tumors | |
| US11697675B2 (en) | EPHA3 and multi-valent targeting of tumors | |
| JP2021502810A5 (enExample) | ||
| JPH04503945A (ja) | 血管透過性抱合体 | |
| US20110262466A1 (en) | Compositions containing thrombomodulin domains and uses thereof | |
| JPH0259128B2 (enExample) | ||
| HRP20030192A2 (en) | Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target specific prodrug | |
| US20180154012A1 (en) | Cancer immunotherapeutic | |
| JP2024517871A5 (enExample) | ||
| JP2022520596A5 (enExample) | ||
| AU4104700A (en) | Antibody and chemokine constructs that are directed to CCR5, and their use for treating autoimmune diseases | |
| Corti | Strategies for improving the anti-neoplastic activity of TNF by tumor targeting | |
| EP4153232A1 (en) | Tnf? immunoconjugate therapy for the treatment of brain tumors | |
| JP2022535816A5 (enExample) | ||
| She et al. | Snoopligase-catalyzed molecular glue enables efficient generation of hyperoligomerized TRAIL variant with enhanced antitumor effect | |
| JP2017095417A (ja) | 抗癌剤 | |
| Liu et al. | Improvement of tumor targeting and antitumor activity by a disulphide bond stabilized diabody expressed in Escherichia coli | |
| WO2017147820A1 (zh) | 双重标靶药物载体 | |
| US11952402B2 (en) | Fusion protein containing trail and IgG binding domain and the uses thereof | |
| US20250382360A1 (en) | Anti-VEGF Single Chain Variable Fusion Protein (RNAT82) | |
| US20250381288A1 (en) | Anti-VEGF Single Chain Variable Fusion Protein (RNAT92) |